

Discrete Choice Experiments (DCEs): Theory and Applications

Seminar RIVM, Bilthoven, the Netherlands

April 9, 2015

Esther W. de Bekker-Grob, PhD

Department of Public Health – Erasmus MC University Medical Centre e.debekker@erasmusmc.nl Erasmus Choice Modelling Centre (www.erim.eur.nl/ecmc)

- What is a Discrete Choice Experiment (DCE)?
- How to conduct a DCE?
- How are DCEs applied and reported in health care?
- Future research

Erasmus M(

- What is a Discrete Choice Experiment (DCE)?
- How to conduct a DCE?
- How are DCEs applied and reported in health care?
- Future research

Erasmus M(

DCEs: What are they?

- Quantitative method to measure benefit/preferences
- Origins in mathematical psychology
- Main practice in marketing, environmental, transport economics

Erasmus M(

DCEs – What are they?

- Introduced in health care early 1990s
- as an economic technique to measure benefit beyond health outcomes.

See e.g. Ryan M, Farrar S. Eliciting preference for healthcare using conjoint analysis. BMJ 2000;320: 1530-3.

Erasmus MC zamo

DCE – Attribute based survey

- DCE is an attribute based survey (economic technique)
- A DCE typically consists of:
 - numerous respondents
 - being asked to complete a number of choice tasks

Erasmus MC zamo

	Program 1	Program 2	No screening
Deaths prostate cancer			
	******************	*******	****************
	18 out of 1000	25 out of 1000	35 out of 1000
Freq blood test	every 3 years	every 4 years	n.a.
Risk unnecessary biopsy	800 out of 1000	400 out of 1000	n.a.
	800 001 01 1000	400 OUL OF 1000	
Risk unnecessary treatment	500 out of 1000	0 out of 1000	n.a.
Out-of-pocket costs annually	€ 50	€ 100	€0
I prefer:	0	0	0

	Program 1	Program 2	No screening
Deaths prostate cancer			
	****	*****	***************
	18 out of 1000	25 out of 1000	35 out of 1000
Freq blood test	every 3 years	every 4 years	n.a.
Risk unnecessary biopsy	800 out of 1000	400 out of 1000	n.a.
Risk unnecessary treatment	500 out of 1000	0 out of 1000	n.a.
Out-of-pocket costs annually	€ 50	€ 100	€ 0
I prefer:	Ο	0	Ο

	Program	1	Pro	gram 2		No screenin	g	
Deaths prostate cancer								
	**********	******	*******		<u>†</u> †††	*************		
	18 out of 100	0	25 out (of 1000	35	out of 1000		
Freq blood test	every 3 ye	ars	every	/ 4 years		n.a.		
Risk unnecessary biopsy	800 out of 1	000	400 out of 1000			n.a.		
Risk unnecessary treatment	500 out of 1	000	0 out of 1000			n.a.		
Out-of-pocket costs annually	€ 50		€	E 100		€0		
I prefer:	0			0		0	2	

DCE – advantage

- Reasonably straightforward task (ordinal instead of cardinal)
- Closely resembles a real world decision
- Many output possibilities (OR, WTP, MRS, utility scores, probs)

Erasmus MC zamo

Research question (some examples)

- What is the willingness to pay to receive a more comprehensive prenatal testing?
- How willing are patients to wait for a treatment in a hospital they prefer?
- How much risk reduction is required to consider treatment X as acceptable?
- How to implement an intervention in an effective way?
- How do individuals weigh the harms and benefits of treatment X?
- How is screening participation affected by the type of screening test?
- What outcomes are important to patients with long term conditions?
- Which uptake can be expected for vaccination against disease X?

Erasmus Mo

11

What do the people in this room value about their jobs?

- What is a Discrete Choice Experiment (DCE)?
- How to conduct a DCE?
- How are DCEs applied and reported in health care?
- Future research

Note: this part contains several slides that are based on the course slides of "Bliemer & Rose. 2011. Course in Stated Choice Methods, Maastricht, the Netherlands" (i.e. slides 13-15, 17, 20, 27, 28, 32 and 34; agreement was received).

Erasmus MC



Determining, what:

- 1 Alternatives
- 2 Attributes
- 3 Attribute levels
- 4 Utility function
- 5 Model
- 6 Statistical design
- 7 Number choice tasks

pre-experimental design decisions

\rightarrow Decisions before we get to the DCE design

For more details, see e.g. Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge: Cambridge University Press, 2005.

Erasmus MC zafing

1. What and how many alternatives?

Attributes	Program A	Program B	No vaccination
Protection against cervical cancer	70%	90%	0%
Protection duration	Lifetime	6 years	n.a.
Serious side effects	very small	very small	No risk
Mild side effects	10 out of 100	2 out of 100	No risk
Age at vaccination	14 years	9 years	n.a.
Which vaccination program do you prefer?	ch vaccination gram do you prefer?		□ None
Attributes	Program A	Program B	
Attributes Protection against cervical cancer	Program A 70%	Program B 90%	
Attributes Protection against cervical cancer Protection duration	Program A 70% Lifetime	Program B 90% 6 years	
Attributes Protection against cervical cancer Protection duration Serious side effects	Program A 70% Lifetime very small	Program B 90% 6 years very small	
Attributes Protection against cervical cancer Protection duration Serious side effects Mild side effects	Program A 70% Lifetime very small 10 out of 100	Program B 90% 6 years very small 2 out of 100	
Attributes Protection against cervical cancer Protection duration Serious side effects Mild side effects Age at vaccination	Program A 70% Lifetime very small 10 out of 100 14 years	Program B90%6 yearsvery small2 out of 1009 years	

Opt-out?

No opt-out?

Erasmus MC april

1. What and how many alternatives?

Attributes	Program A	Program B	No vaccination
Protection against cervical cancer	70%	90%	0%
Protection duration	Lifetime	6 years	n.a.
Serious side effects	very small	very small	No risk
Mild side effects	10 out of 100	2 out of 100	No risk
Age at vaccination	14 years	9 years	n.a.
Which vaccination program do you prefer?		В	□ None
Attributes	Gardasil	Cervarix	No vaccination
Attributes Protection against cervical cancer	Gardasil 70%	Cervarix 90%	No vaccination
Attributes Protection against cervical cancer Protection duration	Gardasil 70% Lifetime	Cervarix90%6 years	No vaccination 0% n.a.
Attributes Protection against cervical cancer Protection duration Serious side effects	Gardasil 70% Lifetime very small	Cervarix90%6 yearsvery small	No vaccination 0% n.a. No risk
Attributes Protection against cervical cancer Protection duration Serious side effects Mild side effects	Gardasil 70% Lifetime very small 10 out of 100	Cervarix90%6 yearsvery small2 out of 100	No vaccination 0% n.a. No risk No risk
Attributes Protection against cervical cancer Protection duration Serious side effects Mild side effects Age at vaccination	Gardasil 70% Lifetime very small 10 out of 100 14 years	Cervarix90%6 yearsvery small2 out of 1009 years	No vaccination0%n.a.No riskNo riskn.a.

Unlabelled?

Labelled?



2. What and how many attributes? Driven by research question

→ Literature, focus groups, expert interviews crucial! ←

Number of attributes too many? Increased error variance Lexicographic behaviour

Always pre-test and pilot your survey!!

Erasmus MC

3. What and how many attribute levels?

Driven by research question

e.g. Do individuals prefer every year, every 2 years or every 5 years screening?

- to test for (non-)linearity, at least 3 levels needed

Erasmus M

4. What will the utility functions of the model look like?

Attributes	Program A	Program B	No vaccination
Protection against cervical cancer	70%	90%	0%
Protection duration	Lifetime	6 years	n.a.
Serious side effects	very small	very small	No risk
Mild side effects	10 out of 100	2 out of 100	No risk
Age at vaccination	14 years	9 years	n.a.
Which vaccination program do you prefer?		В	□ None

Erasmus MC

4. What will the utility functions of the model look like?

Write out the utility functions you expect to estimate:

Vprogram A

 $= \beta_0 + \beta_1 Effect + \beta_2 Duration_25y + \beta_3 Duration_lifetime$ $+ \beta_4 Serious + \beta_5 Mild + \beta_6 Age_12y + \beta_7 Age_14y$

Vprogram B

= $\beta_8 + \beta_1 Effect + \beta_2 Duration_25y + \beta_3 Duration_lifetime$ + $\beta_4 Serious + \beta_5 Mild + \beta_6 Age_12y + \beta_7 Age_14y$

VNo vaccination

 \rightarrow to have an overview of:

how many parameters has to be estimated

= 0

- which attributes are linear/categorical and/or alternative specific

4. What will the utility functions of the model look like?

Write out the utility functions you expect to estimate:

Vprogram A

 $= \beta_0 + \beta_1 Effect + \beta_2 Duration_25y + \beta_3 Duration_lifetime$ $+ \beta_4 Serious + \beta_5 Mild + \beta_6 Age_12y + \beta_7 Age_14y$

Vprogram B

 $= \beta_8 + \beta_1 Effect + \beta_2 Duration_25y + \beta_3 Duration_lifetime$ $+ \beta_4 Serious + \beta_5 Mild + \beta_6 Age_12y + \beta_7 Age_14y$

 $V^{\text{No vaccination}} = 0$

 \rightarrow to have an overview of:

- how many parameters has to be estimated
- which attributes are linear/categorical and/or alternative specific

4. What will the utility functions of the model look like?

Write out the utility functions you expect to estimate:

Vprogram A

 $= \beta_0 + \beta_1 Effect + \beta_2 Duration_25y + \beta_3 Duration_lifetime$ $+ \beta_4 Serious + \beta_5 Mild + \beta_6 Age_12y + \beta_7 Age_14y$

Vprogram B

= $\beta_8 + \beta_1 Effect + \beta_2 Duration_25y + \beta_3 Duration_lifetime$ + $\beta_4 Serious + \beta_5 Mild + \beta_6 Age_12y + \beta_7 Age_14y$

 $V^{\text{No vaccination}} = 0$

 \rightarrow to have an overview of:

- how many parameters has to be estimated
- which attributes are linear/categorical and/or alternative specific

4. What will the utility functions of the model look like?

Write out the utility functions you expect to estimate:

Vprogram A

 $= \beta_0 + \beta_1 Effect + \beta_2 Duration_25y + \beta_3 Duration_lifetime$ $+ \beta_4 Serious + \beta_5 Mild + \beta_6 Age_12y + \beta_7 Age_14y$

Vprogram B

 $= \beta_8 + \beta_1 Effect + \beta_2 Duration_25y + \beta_3 Duration_lifetime$ $+ \beta_4 Serious + \beta_5 Mild + \beta_6 Age_12y + \beta_7 Age_14y$

 $V^{\text{No vaccination}} = 0$

 \rightarrow to have an overview of:

- how many parameters has to be estimated
- which attributes are linear/categorical and/or alternative specific

5. What model will most likely to be estimated after data collection?







6. What statistical properties should the design display? There are a lot of different designs one can choose

Full factorial designs Non-full factorial designs Orthogonal designs Efficient designs Bayesian efficient designs

. . . .

Depends on preferred statistical properties, the information available, and the preferred size of the design

For more details: see e.g. Reed Johnson F et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013 Jan-Feb;16(1):3-13.

Erasmus MC

7. How many choice tasks should be included in the design?



	Α	В	С	D	Е	Α	В	С	D	Е
1	0	0	0	0	0	1	1	1	1	1
2	0	1	1	1	1	1	2	2	2	2
3	0	2	2	2	2	1	3	3	3	3
4	0	3	3	3	3	1	0	0	0	0
5	1	0	1	2	3	2	1	2	3	0
6	1	1	0	3	2	2	2	1	0	3
7	1	2	3	0	1	2	3	0	1	2
8	1	3	2	1	0	2	0	3	2	1
9	2	0	2	3	1	3	1	3	0	2
10	2	1	3	2	0	3	2	0	3	1
11	2	2	0	1	3	3	3	2	2	0
12	2	3	1	0	2	3	0	2	1	3
13	3	0	3	1	2	0	1	0	2	3
14	3	1	2	0	3	0	2	3	1	0
15	3	2	1	3	0	0	3	2	0	1
16	3	3	0	2	1	0	0	1	3	2

Respondent perspective

Statistical design perspective

Erasmus MO

7. How many choice tasks should be included in the design?



Respondent perspective

Burden and fatigue

Learning effect

Erasmus MC

7. How many choice tasks should be included in the design?

Statistical design perspective

Each parameter requires a degree of freedom:

- alternative specific constant(s)
- main effects
- interaction effects

etc.

That's why writing out the expected utility functions is important!

Erasmus MC

				~	D	C		- L	~	U.	C	
			1	0	0	0	0	0	1	1	1	1
			2	0	1	1	1	1	1	2	2	2
De	termining, what:		3	0	2	2	2	2	1	3	3	3
1	Alternatives		4	0	3	3	3	3	1	0	0	0
_			5	1	0	1	2	3	2	1	2	3
2	Attributes		6	1	1	0	3	2	2	2	1	0
3	Attribute levels	-	7	1	2	3	0	1	2	3	0	1
л			8	1	3	2	1	0	2	0	3	2
4	Utility function		9	2	0	2	3	1	3	1	3	0
5	Model		10	2	1	3	2	0	3	2	0	3
6	Statistical docign		11	2	2	0	1	3	3	3	2	2
0	Statistical design		12	2	3	1	0	2	3	0	2	1
7	Number choice tasks		13	3	0	3	1	2	0	1	0	2
			14	3	1	2	0	3	0	2	3	1
			15	3	2	1	3	0	0	3	2	0
			16	3	3	0	2	1	0	0	1	3
n	ra avparimental											

design decisions

experimental design combi of attribute levels

> Erasmus MC Calmo

Full factorial designs

Designs in which all possible choice situations are included

For example:

Assuming an unlabelled design (2 options per choice set)

- 2 attributes with 3 levels \rightarrow 3^2 = 9 alternatives (choice situations) \rightarrow 9*((9-1)/2) = 36 choice sets
- 3 attributes with 3 levels \rightarrow 3^3 = 27 alternatives (choice situations) \rightarrow 27*((27-1)/2) = 351 choice sets
- 4 attributes with 3 levels \rightarrow 3⁴ = 81 (choice situations) \rightarrow 81*((81-1)/2) = 3,240 choice sets

Erasmus MC

Full factorial designs

How to reduce the number of choice situations? Reduce the number of attributes Reduce the number of attribute levels Create a non-full factorial design ...



Non-full factorial designs

Designs that use a subset of choice situations

Advantage Reduction of the number of choice situations shown to each respondent

Disadvantage

Because only a fraction of the choice situations is used, not all effects can be measured

Note

Remember there is a lower bound on the number of choice situations.

Erasmus Mo

Non-full factorial designs

	Orthogonal designs	Optimal orthogonal designs	(Bayesian) efficient designs	Optimal choice prob designs
Widely used	+	-	F	-
Ease of generation	-	-	-/+	+
Efficiency of design	-	-/+	+	+
Prior parameter info needed	+	+	-	-
Model flexibility	-/+	-	+	-

Adapted from Bliemer & Rose. 2011. Course in Stated Choice Methods, Maastricht

Erasmus MC



- 1 Alternatives
- 2 Attributes
- 3 Attribute levels
- 4 Utility function
- 5 Model
- 6 Statistical design
- 7 Number choice tasks

pre-experimental design decisions

A B C D E A B C D E 10000011111 <u>1 1 1 1 1 2 2 2 2 </u> 2 0 2 2 2 1 3 3 3 3 3 0 2 33310000 3 12321230 0 032221 03 01230 1 2 3 <mark>8 1 3 2 1 0</mark> 2 0 3 2 1 2023131302 <u>10 2 1 3 2 0 3 2 0 3 1</u> <u>11 2 2 0 1 3</u> 3 3 2 2 0 <u>12 2 3 1 0 2</u> 3 0 2 1 3 <u>13 3 0 3 1 2 0 1 0 2 3</u> <u>14 3 1 2 0 3 0 2 3 1 0</u> <u>15 3 2 1 3 0</u> 0 3 2 0 1 <u>16 3 3 0 2 1</u> 0 0 1 3 2

experimental design combi of attribute levels



questionnaire

Always pre-test and pilot your survey!!

Erasmus MC Trafung



- Paper & pencil, panel data, interviewer based,...
- Sample size (for more information, see De Bekker-Grob et al. 2015. Sample size requirements for discrete choice experiments in health care: a practical guide. Patient.)





Content

- What is a Discrete Choice Experiment (DCE)?
- How to conduct a DCE?
- How are DCEs applied and reported in health care?
- Future research

Erasmus MC zam



Publication year

Overview DCE practice (1)

	1990-2000¹	2001-2008 ²	2009-2012 ³
Country of origin	(n=34)	(n=114)	(n=178)
	0⁄0	%	0⁄0
UK	59	48	22
US	21	12	16
Australia	18	11	7
Canada	3	5	11
Denmark	0	4	6
Netherlands	0	4	14
Germany	0	3	9
Other	0	11	25

Systematic reviews:

¹ Ryan, Gerard. Appl Health Econ Health Policy. 2003

- ² de Bekker-Grob, Ryan, Gerard. Health Econ. 2012
- ³ Clark, Determann, Petrou, Moro, de Bekker-Grob. PharmaEcon. 2014

Erasmus MC Cafung

Overview DCE practice (2)

		1990-2000¹	$2001-2008^2$	2009-2012³
	Main study objective	(n=34)	(n=114)	(n=178)
		%	%	%
(A)	Valuing experience factors	35	35	12
(B)	Valuing health outcomes	9	7	б
(C)	Trade-offs health outcomes & experience factors	41	33	41
(D)	Utility weights within QALY framework	0	2	2
(E)	Job-choices	6	4	6
(F)	Developing priority setting frameworks	6	5	13
(G)	Health professional's preferences	3	15	12
(H)	Other	0	4	10

Note * Percentages do not add up to 100% as several studies had more than one main objective

Erasmus MC zafing

Overview DCE practice (3)

		1990-2000	2001-2008	2009-2012
		(n=34)	(n=114)	(n=178)
		%	%	%
Number of attributes	2-3	15	13	9
	4-5	29	44	33
	6	26	26	34
	7-9	12	13	22
	10	6	2	2
	>10	12	2	2
Attributes covered*	Monetary measure	56	54	56
	Time	74	51	66
	Risk	35	31	57
	Health status domain	56	54	61
	Health care	82	69	72
	Other	9	15	47
* Percentages do not add	d up to 100% as studies use	e many attribut	es	
			43	< C cayo

Overview DCE practice (4)

		1990-2000	2001-2008	2009-2012
		(n=34)	(n=114)	(n=178)
		%	%	%
Number of choices per	8 or less choices	38	39	21
respondenent	9-16 choices	53	38	62
	More than 16 choices	6	18	15
	Not clearly reported	3	4	4
Administration of	Self-complete	79	67	48
survey*	questionnaire			
	Interviewer	9	19	17
	administered			
	Computerised	9	11	40
	interview			
	Not reported	3	8	3
* Percentages do not add up to 100% as studies use multiple methods				

Erasmus MC

		1990-2000	2001-2008	2009-2012
		(n=34)	(n=114)	(n=178)
		%	%	%
Design source	Software package	56	52	53
	SPEED	38	19	4
	SPSS	6	12	6
	SAS	0	12	21
	SAWTOOTH	6	4	13
	Other	6	0	8
	No further details	0	4	4
	Catalogue	6	5	10
	Website	0	3	5
	Expert	12	4	6
	Not clearly reported	26	37	26
Method to create	Orthogonal rays			
choice sets*	Single profiles (i.e. binary choices)	9	11	1
	Random pairing	53	17	10
	Pairing with constant comparator	18	20	3
	Foldover - random pairing	0	1	2
	Foldover	0	10	17
	D-efficiency	0	12	30
	Other (pragmatically chosen)	12	2	5
	Not clearly reported	9	28	26
	Other	N / A	N / A	10

Overview DCE practice (6)

		1990-2000	2001-2008	2009-2012
		(n=34)	(n=114)	(n=178)
		%	%	%
Estimation procedure*	Probit	18	7	2
	Random effects probit	53	41	10
	Logit	3	11	10
	Random effects logit	3	5	8
	MNL	18	22	43
	Nested logit (NL)	0	4	2
	Mixed logit (MXL)	3	5	10
	Latent class (LCM)	0	1	3
	Other	3	4	17
	Not clearly reported	6	4	1
Note: * Totals do not add up to 100% as some studies use multiple estimation procedures				

Erasmus MC

Overview DCE practice (7)

		1990-2000	2001-2008	2009-2012
		(n=34)	(n=114)	(n=178)
		%	%	%
Validity test*	External	0	1	<1
	Internal:			
	Theoretical	65	56	60
	Non-satiation	44	49	21
	Transitivity	9	4	1
	Sen's expansion and contraction	0	2	1
	Compensatory decision making	35	32	14

Note: * Totals do not add up to 100% as some studies use multiple validity tests

Erasmus MC - zafing

- DCEs commonly used instrument in health care
- Covering wide range of policy questions
- Broad range of health-care systems
- A shift towards
 - Statistically more efficient designs
 - Flexible econometric models
- External validity tests are limited

Erasmus MC Cafing

Content

- What is a Discrete Choice Experiment (DCE)?
- How to conduct a DCE?
- How are DCEs applied and reported in health care?
- Future research

Erasmus MC zamo

Future research

Among others.....

- External validity
- Incorporating DCE results into a decision-making framework
- Complexity (e.g. level overlap, colour coding, presenting risk)
- Eye-tracking
- Advanced choice models and utility functions
- Random regret minimization models
- DCE for QALY estimation

Erasmus MC

QUESTIONS?



e.debekker@erasmusmc.nl

See also: Erasmus Choice Modelling Centre (www.erim.eur.nl/ecmc)

Erasmus MC zafing